Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation—a registry study on behalf of the EBMT Acute Leukemia Working Party
Klaus Hirschbühl, Myriam Labopin, Mohamed Houhou, Ludovic Gabellier, Hélène Labussière‐Wallet, Bruno Lioure, Dietrich W. Beelen, Jan J. Cornelissen, Gerald Wulf, Pavel Jindra, Hervé Tilly, Jakob Passweg, Riita Niittyvuopio, Gesine Bug, Christoph Schmid, Arnon Nagler, Sebastian Giebel, Mohamad Mohty
Topics & Concepts
MedicineDasatinibPonatinibInternal medicineTransplantationNilotinibDiscontinuationMinimal residual diseaseAcute lymphocytic leukemiaOncologyAcute leukemiaTyrosine-kinase inhibitorStem cellPhiladelphia chromosomeHematopoietic stem cell transplantationLeukemiaImatinibMyeloid leukemiaLymphoblastic LeukemiaCancerChromosomal translocationChemistryBiochemistryBiologyGeneGeneticsChronic Myeloid Leukemia TreatmentsAcute Lymphoblastic Leukemia researchQuinazolinone synthesis and applications